YK-11 Receptor & Signaling Pathways — Research Reference
YK-11 functions as a distinct research compound, intriguing scientists due to its documented agonistic activity at the androgen receptor (AR) and its concurrent myostatin-inhibiting properties. Research into YK-11 investigates its unique dual mechanism, offering insights into potential signaling pathway modulation within various biological systems. Its classification as a selective androgen receptor modulator (SARM) and myostatin modulator has led to its extensive study in preclinical models.
This compound, while steroidal in structure, is primarily examined for its tissue-selective effects, differentiating it from traditional androgens. The scientific community has published numerous studies indexed on PubMed, detailing YK-11’s interactions with cellular machinery. Additionally, several registered studies on ClinicalTrials.gov highlight the ongoing research interest in understanding its mechanisms and potential therapeutic relevance, solely within a controlled research context.
YK-11: A Dual Modulator – Androgen Receptor and Myostatin Antagonism
YK-11 is a steroidal compound of significant interest in preclinical research, primarily characterized by its dual mechanistic profile as both a Selective Androgen Receptor Modulator (SARM) and a potential myostatin modulator. This unique combination positions YK-11 as a compound under investigation for its capacity to influence cellular processes traditionally governed by androgenic signaling while simultaneously impacting regulatory pathways associated with skeletal muscle mass and growth. Its chemical structure, a derivative of 5-α-dihydrotestosterone (DHT), provides a foundational understanding for its interaction with the androgen receptor (AR), yet its downstream effects in various research models suggest a more nuanced and selective activity profile than that observed with traditional androgens. The study of YK-11 within controlled laboratory settings aims to dissect these intricate interactions and their implications for tissue-specific responses, particularly within muscle and bone research models.
The SARM classification of YK-11 implies a differential agonistic activity in various tissues, aiming to promote anabolic effects in muscle and bone while minimizing androgenic effects in tissues such as prostate or skin in research models. This selective action is a hallmark of SARMs, distinguishing them from broad-spectrum androgens which activate the AR ubiquitously. Research endeavors involving YK-11 often seek to quantify this selectivity ratio in preclinical models, evaluating its binding affinity to the AR, subsequent transcriptional activation, and the resultant physiological changes across different tissue types. Understanding the molecular basis for this selectivity is crucial for advancing the utility of YK-11 as a research tool, offering insights into androgen receptor biology and the potential for targeted modulation of anabolic pathways.
Beyond its SARM properties, YK-11 has garnered attention for its hypothesized role as a myostatin modulator. Myostatin, a member of the TGF-β superfamily, is a well-established negative regulator of muscle growth, primarily by inhibiting myogenesis and promoting muscle atrophy. The proposition that YK-11 may interfere with this pathway, either directly by binding to myostatin or its receptors, or indirectly through modulating downstream signaling components, adds another layer of complexity and research interest. This dual mechanism suggests a potentially synergistic approach to influencing muscle anabolism in research models, where both androgen receptor activation and myostatin pathway attenuation could contribute to enhanced protein synthesis and satellite cell differentiation. Investigations into YK-11’s impact on myostatin expression and activity are therefore a central theme in many research designs.
The Steroidal Backbone and Functional Group Interactions
The steroidal structure of YK-11 is integral to its biological activity. As a 17α,20-epoxy-17,20-[(1-methoxyethylidene)bis(oxy)]-3-oxo-19-norpregna-4,9-diene, its unique modifications from DHT contribute to its specific binding characteristics and its stability in biological systems. Researchers often focus on structure-activity relationship (SAR) studies to understand how specific functional groups on the YK-11 molecule contribute to its AR selectivity and potential myostatin modulatory effects. These studies often involve synthesizing analogs and testing their efficacy in *in vitro* assays and *in vivo* animal models to pinpoint critical structural elements responsible for the observed dual action.
The Concept of Dual Modulation in Research
The concept of a dual modulator like YK-11 presents novel avenues for research into complex biological systems. Rather than focusing on a single signaling pathway, investigators can explore the integrated effects of simultaneously targeting the androgen receptor and the myostatin pathway. This approach could reveal intricate crosstalk between these pathways and how their combined modulation impacts various physiological endpoints, such as muscle hypertrophy, strength, and recovery in preclinical models. Such studies contribute valuable data to the broader understanding of anabolic processes and muscle wasting conditions, serving as a foundation for future mechanistic explorations.
Elucidating Androgen Receptor Binding and Transcriptional Activity
The interaction of YK-11 with the androgen receptor (AR) is a cornerstone of its proposed mechanism of action, making detailed investigation into its binding kinetics and subsequent transcriptional effects paramount in research. The androgen receptor, a ligand-activated transcription factor, is part of the nuclear receptor superfamily and plays a critical role in regulating gene expression involved in various physiological processes, including skeletal muscle development, bone maintenance, and erythropoiesis. YK-11, as a steroidal SARM, is hypothesized to bind to the ligand-binding domain (LBD) of the AR with high affinity, initiating a conformational change that promotes its translocation to the nucleus, dimerization, and binding to specific DNA sequences known as androgen response elements (AREs) within the promoter regions of target genes.
Research into YK-11’s AR binding typically employs a range of *in vitro* methodologies. Competitive binding assays, utilizing radiolabeled or fluorescently tagged reference ligands, are commonly used to determine YK-11’s affinity for the AR relative to endogenous androgens like testosterone or dihydrotestosterone (DHT). These studies help establish its potency as an AR ligand. Following binding, the primary functional outcome is transcriptional activation. Reporter gene assays, where a luciferase or β-galactosidase gene is placed downstream of an ARE, are instrumental in quantifying the transcriptional activity induced by YK-11 in various cell lines expressing the AR. These assays allow researchers to compare YK-11’s efficacy and potency in activating AR-dependent gene transcription against a panel of known AR agonists and antagonists, providing critical insights into its pharmacological profile.
Specificity and Selectivity in AR Interaction
A distinguishing feature of SARMs, including YK-11, is their purported tissue-selective activity. This selectivity is not solely determined by binding affinity but also by the interaction with co-activator and co-repressor proteins that are differentially expressed across tissues. In skeletal muscle and bone research models, YK-11 is hypothesized to preferentially recruit co-activators that promote anabolic gene expression, while in other tissues, it may either recruit co-repressors or simply exhibit attenuated activity. Advanced research methodologies, such as chromatin immunoprecipitation sequencing (ChIP-seq) and quantitative polymerase chain reaction (qPCR), are employed to map YK-11-induced AR binding sites across the genome and quantify the expression of downstream target genes in specific research models, helping to elucidate this tissue specificity.
Further investigation into the AR interaction focuses on the precise conformational changes induced by YK-11 binding. Structural biology techniques, such as X-ray crystallography or nuclear magnetic resonance (NMR) spectroscopy of the AR-LBD in complex with YK-11, could provide atomic-level details about the ligand-receptor interface. Such data are invaluable for understanding the molecular basis of its agonistic activity and tissue selectivity. Moreover, studies involving mutant AR receptors or cells with altered co-factor profiles can help dissect the intricate network of interactions that mediate YK-11’s specific transcriptional responses, contributing to a more complete picture of its mechanism of action as explored in the YK-11 Mechanism of Action research reference.
Investigating Gene Expression Profiles
Beyond individual reporter assays, comprehensive gene expression profiling using techniques like RNA sequencing (RNA-seq) provides a global view of the transcriptional changes induced by YK-11 in research models. By comparing the transcriptomic landscape of YK-11-treated cells or tissues with control groups and those treated with traditional androgens or other SARMs, researchers can identify unique sets of genes regulated by YK-11. This holistic approach can reveal novel AR target genes, provide insights into the downstream signaling cascades, and corroborate its selective anabolic properties in muscle and bone cells. These studies are crucial for fully understanding the broad impact of YK-11’s AR agonism.
The Myostatin Pathway: A Key Regulatory Target for YK-11 Research
The myostatin pathway stands as a critical negative regulator of skeletal muscle mass, and its modulation by YK-11 represents a significant area of preclinical research. Myostatin (GDF-8) is a potent catabolic factor belonging to the transforming growth factor-beta (TGF-β) superfamily. It is primarily expressed in skeletal muscle and acts as an endocrine, autocrine, and paracrine factor to limit muscle growth and size. The canonical myostatin signaling pathway is initiated when myostatin binds to its primary receptor, activin receptor type IIB (ActRIIB), on the surface of muscle cells. This binding leads to the recruitment and phosphorylation of activin receptor-like kinase (ALK) receptors, specifically ALK4 and ALK5, forming a heteromeric receptor complex.
Upon activation of the receptor complex, the intracellular signaling cascade primarily involves the phosphorylation of Smad2 and Smad3 proteins (R-Smads). These phosphorylated Smad proteins then form a complex with Smad4 (Co-Smad), translocate to the nucleus, and bind to specific DNA sequences to regulate the transcription of target genes. The net effect of this Smad-dependent signaling is the inhibition of myoblast proliferation, differentiation, and protein synthesis, ultimately leading to reduced muscle accretion. Research into YK-11’s interaction with this pathway is driven by the hypothesis that by attenuating myostatin signaling, YK-11 could promote muscle growth beyond what is achieved through AR activation alone, offering a novel strategy for influencing muscle mass in research models.
Mechanisms of Myostatin Modulation
The precise mechanism by which YK-11 may modulate the myostatin pathway is a subject of ongoing investigation in preclinical research. Several hypotheses are being explored. One prominent theory suggests that YK-11 may directly or indirectly reduce myostatin gene expression or protein levels within muscle tissue. This could occur through transcriptional regulation, potentially mediated by its AR agonistic properties or through other unexplored intracellular signaling cascades. Another hypothesis posits that YK-11 could interfere with myostatin’s binding to its receptor, ActRIIB, or modulate the downstream Smad signaling cascade, thereby inhibiting the catabolic effects even in the presence of myostatin. Additionally, YK-11 could potentially upregulate the expression of myostatin antagonists, such as follistatin, which binds to myostatin and prevents its interaction with ActRIIB.
Research methodologies employed to investigate YK-11’s myostatin modulatory effects include quantitative PCR to measure myostatin and follistatin mRNA levels, Western blotting to assess protein expression of myostatin, ActRIIB, phosphorylated Smad2/3, and total Smad2/3, and luciferase reporter assays using constructs driven by myostatin-responsive elements. *In vitro* muscle cell culture models, such as C2C12 myoblasts, are commonly used to evaluate the effects of YK-11 on myoblast proliferation, differentiation (indicated by fusion index and expression of myotube-specific proteins), and protein synthesis, often in the presence of exogenous myostatin to assess rescue effects. These studies contribute to understanding whether YK-11 primarily acts upstream to reduce myostatin availability or downstream to block its signaling.
Crosstalk with Anabolic Pathways
The potential for YK-11 to concurrently modulate both the androgen receptor and myostatin pathways highlights a complex interplay between anabolic and catabolic signals within skeletal muscle. Research endeavors are focused on understanding how these pathways might converge or interact. For instance, AR activation is known to influence the expression of various growth factors and signaling molecules that can indirectly affect myostatin expression or sensitivity. Conversely, attenuating myostatin signaling could create a more permissive environment for AR-mediated anabolic effects. Investigating this crosstalk is critical for elucidating the full spectrum of YK-11’s actions and for identifying potential synergistic effects that could be exploited in future research into muscle wasting conditions in preclinical models. This area of research is particularly complex and often requires sophisticated multi-omics approaches to unravel the intricate regulatory networks involved.
Downstream Signaling Cascades in Skeletal Muscle Research Models
The distinct dual action of YK-11 as a SARM and a myostatin modulator necessitates a thorough examination of its downstream signaling cascades within skeletal muscle research models. The ultimate goal of modulating both androgen receptor (AR) and myostatin pathways is to promote anabolism and counteract catabolism, leading to observable changes in muscle mass, strength, and function in controlled research environments. The convergence of these two pathways on key signaling nodes that regulate protein synthesis, degradation, and satellite cell activity is a primary focus of investigation. Understanding these cascades provides mechanistic insights into how YK-11 may exert its effects in various preclinical models.
One of the most critical downstream pathways influenced by anabolic stimuli, including AR activation, is the mammalian target of rapamycin (mTOR) pathway. mTOR complex 1 (mTORC1) is a central regulator of protein synthesis, cell growth, and proliferation. Activation of the AR by agonists like YK-11 is hypothesized to stimulate the Akt/mTORC1 pathway, leading to increased phosphorylation of downstream targets such as S6 kinase 1 (S6K1) and eukaryotic initiation factor 4E-binding protein 1 (4E-BP1). Phosphorylation of S6K1 enhances the translation of ribosomal proteins and elongation factors, while phosphorylation of 4E-BP1 liberates eIF4E, facilitating the initiation of mRNA translation. In parallel, myostatin typically inhibits the Akt/mTORC1 pathway, so any attenuation of myostatin signaling by YK-11 could further enhance this anabolic cascade, creating a potentially synergistic effect on protein synthesis in muscle cells.
Regulation of Protein Synthesis and Degradation
Beyond the mTOR pathway, YK-11’s impact on protein turnover involves a delicate balance between synthetic and degradative processes. Research in skeletal muscle models often investigates its effects on muscle protein synthesis (MPS) rates, using methods such as stable isotope tracer incorporation. Simultaneously, the compound’s potential to inhibit muscle protein degradation (MPD) is explored, particularly concerning the ubiquitin-proteasome system and autophagy-lysosome pathway. Myostatin is known to upregulate E3 ubiquitin ligases like atrogin-1 (MAFbx) and MuRF1, which are key components of the ubiquitin-proteasome pathway, leading to muscle protein breakdown. If YK-11 effectively modulates the myostatin pathway, it could potentially downregulate the expression or activity of these catabolic enzymes, thereby preserving muscle mass. The combined effect of stimulating MPS via AR/Akt/mTOR and inhibiting MPD via myostatin antagonism would represent a powerful anabolic strategy in research models.
Furthermore, YK-11’s influence on satellite cells, the resident stem cells of skeletal muscle, is a crucial area of investigation. Satellite cells are essential for muscle repair, regeneration, and hypertrophy. AR activation can stimulate satellite cell proliferation and differentiation, contributing to muscle growth. Conversely, myostatin inhibits satellite cell activation and differentiation. Therefore, YK-11’s dual mechanism could promote satellite cell activity through both pathways: directly via AR agonism and indirectly by relieving myostatin-mediated inhibition. Research focuses on quantifying satellite cell numbers, proliferation rates, and fusion into existing muscle fibers or de novo myotube formation in response to YK-11 treatment in various *in vitro* and *in vivo* models, providing a comprehensive understanding of its regenerative potential.
Key Signaling Components Under Investigation
- Akt/PKB Pathway: Central to cell growth, survival, and metabolism. YK-11 is investigated for its potential to increase Akt phosphorylation, leading to activation of downstream anabolic targets.
- mTORC1 Pathway: The primary regulator of protein synthesis. Research examines phosphorylation states of mTOR, S6K1, and 4E-BP1 in response to YK-11.
- MAPK/ERK Pathway: Involved in cell proliferation, differentiation, and survival. While less directly linked to AR and myostatin, crosstalk may exist, and its modulation by YK-11 could contribute to overall anabolic effects.
- FOXO Transcription Factors: Downstream targets of Akt, often promoting atrophy-related gene expression. YK-11’s potential to inhibit FOXO activity, thereby suppressing catabolic pathways, is explored.
- Myostatin-Smad Pathway: As detailed previously, phosphorylation of Smad2/3 and their nuclear translocation are key indicators of myostatin pathway activity, which YK-11 is hypothesized to suppress.
These investigations often leverage techniques such as Western blotting for protein phosphorylation analysis, immunohistochemistry for protein localization and cell counting, and gene expression profiling via qPCR or RNA-seq to characterize the global transcriptional changes induced by YK-11 in muscle tissues from research models. For insights into proper handling and maintenance of research compounds, refer to the YK-11 Storage and Handling guidelines.
Investigating Bone Tissue Modulatory Properties of YK-11
Beyond its primary focus on skeletal muscle, YK-11’s potential modulatory effects on bone tissue represent another critical area of preclinical research, given its classification as a SARM. Androgen receptors (ARs) are expressed in various bone cells, including osteoblasts (bone-forming cells), osteocytes (mature bone cells), and osteoclasts (bone-resorbing cells). Androgens play a crucial role in maintaining bone mineral density (BMD) and promoting bone formation, particularly in males. Consequently, SARMs like YK-11 are investigated for their ability to exert anabolic effects on bone, potentially by selectively activating ARs in osteoblasts and osteocytes, thereby promoting bone formation while minimizing adverse effects seen with systemic androgen therapy in research models.
Research into YK-11’s bone tissue modulatory properties often begins with *in vitro* studies using osteoblast cell lines (e.g., MC3T3-E1, MG-63) or primary osteoblast cultures. These studies assess YK-11’s direct impact on osteoblast proliferation, differentiation, and mineralization. Key indicators include alkaline phosphatase (ALP) activity, a marker of early osteoblast differentiation, and the formation of mineralized nodules, indicative of mature bone matrix production. Researchers also evaluate the expression of osteoblast-specific genes such as osteocalcin, collagen type I alpha 1 (COL1A1), and runt-related transcription factor 2 (RUNX2) via qPCR or Western blotting, to determine YK-11’s capacity to induce an osteogenic phenotype in these cell models.
Signaling Pathways in Bone Remodeling
The anabolic effects of androgens on bone are mediated through complex signaling pathways, and YK-11 is hypothesized to engage many of these. One prominent pathway is the Wnt/β-catenin signaling pathway, which is a critical regulator of bone formation. Activation of ARs can lead to the stabilization and nuclear translocation of β-catenin, which then complexes with T-cell factor/lymphoid enhancer factor (TCF/LEF) transcription factors to promote the expression of osteogenic genes. Research aims to determine if YK-11 can activate Wnt/β-catenin signaling in osteoblasts, contributing to enhanced bone formation. Other pathways, such as the IGF-1/Akt pathway, which promotes osteoblast survival and activity, are also investigated for their potential modulation by YK-11 in bone research models.
*In vivo* studies using rodent models (e.g., ovariectomized rats/mice as models of estrogen deficiency-induced bone loss, or orchiectomized rats/mice as models of androgen deficiency-induced bone loss) are essential for validating *in vitro* findings and assessing the systemic effects of YK-11 on bone. These studies typically involve long-term administration of YK-11, followed by analyses of BMD using dual-energy X-ray absorptiometry (DXA) or micro-computed tomography (μCT) scans of key skeletal sites like the femur and lumbar vertebrae. Histomorphometric analyses of bone sections provide detailed information on bone turnover parameters, including bone formation rate, trabecular thickness, and cortical width, allowing researchers to quantify YK-11’s impact on bone microstructure and strength.
Investigating Osteoclast Activity
While promoting osteoblast activity, SARMs are also studied for their potential to influence osteoclast activity, which is responsible for bone resorption. Excessive osteoclast activity can lead to bone loss. Therefore, studies often examine YK-11’s effects on osteoclast differentiation from precursor cells (e.g., RAW 264.7 cells or bone marrow macrophages) and their resorptive capacity in *in vitro* pit formation assays. It is hypothesized that YK-11, by selectively activating ARs, could indirectly suppress osteoclastogenesis or directly modulate osteoclast function, contributing to a net increase in bone mass. The balance between osteoblast and osteoclast activity is crucial for maintaining bone homeostasis, and YK-11’s ability to favorably shift this balance is a key area of research.
| Bone Cell Type | Potential YK-11 Effect (Hypothesized) | Key Research Readouts |
|---|---|---|
| Osteoblasts (bone-forming) | Increased proliferation, differentiation, matrix mineralization, enhanced osteogenic gene expression. | ALP activity, mineralized nodule formation, RUNX2, COL1A1, Osteocalcin gene/protein levels. |
| Osteocytes (mature bone cells) | Improved survival, modulation of mechanosensing and signaling to other bone cells. | Sclerostin expression, dentin matrix protein 1 (DMP1), fibroblast growth factor 23 (FGF23). |
| Osteoclasts (bone-resorbing) | Reduced differentiation, decreased resorptive activity, modulation of RANKL/OPG balance. | TRAP activity, pit formation assays, Cathepsin K, NFATc1 gene/protein levels. |
For additional information on the broader range of YK-11 research applications, consult the YK-11 Research page.
Comparative Preclinical Research: YK-11 vs. Traditional Androgens
Comparative preclinical research is indispensable for positioning YK-11 within the landscape of anabolic compounds, particularly against traditional androgens such as testosterone and dihydrotestosterone (DHT).
Frequently Asked Questions
What is YK-11’s primary classification in research?
YK-11 is primarily classified as a steroidal compound studied for its activity as a selective androgen receptor modulator (SARM) and a myostatin modulator within research contexts.
How does YK-11 interact with the androgen receptor?
Research indicates YK-11 acts as an agonist or partial agonist at the androgen receptor, influencing gene transcription in a tissue-selective manner, particularly within muscle and bone tissue models.
What is the significance of YK-11’s interaction with the myostatin pathway?
YK-11 is researched for its ability to antagonize myostatin activity, a protein known to inhibit muscle growth, potentially through mechanisms involving follistatin upregulation in preclinical studies.
What research models are typically used to study YK-11?
YK-11 is extensively studied in *in vitro* cell culture models (e.g., myoblasts, osteoblasts) and *in vivo* animal models (e.g., rodents) to investigate its molecular mechanisms and physiological effects.
Is YK-11 considered a traditional anabolic steroid?
While YK-11 possesses a steroidal chemical structure, it is often investigated as a SARM due to its purported selective tissue activity, aiming to differentiate its research profile from traditional, less-selective anabolic steroids.
Can YK-11 be used for human medical purposes?
No, YK-11 is strictly for research use only and is not approved or indicated for human consumption or medical purposes. All discussions of YK-11 pertain solely to its role as a research chemical.
What types of signaling pathways are influenced by YK-11 in research?
Research suggests YK-11 influences various signaling pathways, including the androgen receptor signaling pathway, the TGF-β/SMAD pathway (via myostatin), and potentially the PI3K/Akt/mTOR pathway in skeletal muscle cells.
Where can researchers find peer-reviewed information on YK-11?
Researchers can find numerous peer-reviewed publications on YK-11 and its mechanisms by searching scientific databases such as PubMed and investigating clinical trial registries like ClinicalTrials.gov for registered studies.
Scientific References
All information from Royal Peptide Labs is provided for in-vitro laboratory and research use only — not for human, veterinary, diagnostic, or therapeutic use.